208 related articles for article (PubMed ID: 19509253)
1. Vorinostat enhances the radiosensitivity of a breast cancer brain metastatic cell line grown in vitro and as intracranial xenografts.
Baschnagel A; Russo A; Burgan WE; Carter D; Beam K; Palmieri D; Steeg PS; Tofilon P; Camphausen K
Mol Cancer Ther; 2009 Jun; 8(6):1589-95. PubMed ID: 19509253
[TBL] [Abstract][Full Text] [Related]
2. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, enhances radiosensitivity and suppresses lung metastasis in breast cancer in vitro and in vivo.
Chiu HW; Yeh YL; Wang YC; Huang WJ; Chen YA; Chiou YS; Ho SY; Lin P; Wang YJ
PLoS One; 2013; 8(10):e76340. PubMed ID: 24130769
[TBL] [Abstract][Full Text] [Related]
3. Suberoylanilide hydroxamic acid (Zolinza/vorinostat) sensitizes TRAIL-resistant breast cancer cells orthotopically implanted in BALB/c nude mice.
Shankar S; Davis R; Singh KP; Kurzrock R; Ross DD; Srivastava RK
Mol Cancer Ther; 2009 Jun; 8(6):1596-605. PubMed ID: 19509267
[TBL] [Abstract][Full Text] [Related]
4. Vorinostat inhibits brain metastatic colonization in a model of triple-negative breast cancer and induces DNA double-strand breaks.
Palmieri D; Lockman PR; Thomas FC; Hua E; Herring J; Hargrave E; Johnson M; Flores N; Qian Y; Vega-Valle E; Taskar KS; Rudraraju V; Mittapalli RK; Gaasch JA; Bohn KA; Thorsheim HR; Liewehr DJ; Davis S; Reilly JF; Walker R; Bronder JL; Feigenbaum L; Steinberg SM; Camphausen K; Meltzer PS; Richon VM; Smith QR; Steeg PS
Clin Cancer Res; 2009 Oct; 15(19):6148-57. PubMed ID: 19789319
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo radiosensitization induced by hydroxyapatite nanoparticles.
Chu SH; Karri S; Ma YB; Feng DF; Li ZQ
Neuro Oncol; 2013 Jul; 15(7):880-90. PubMed ID: 23519742
[TBL] [Abstract][Full Text] [Related]
6. Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of gamma-H2AX foci.
Munshi A; Tanaka T; Hobbs ML; Tucker SL; Richon VM; Meyn RE
Mol Cancer Ther; 2006 Aug; 5(8):1967-74. PubMed ID: 16928817
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo radiosensitization with AZD6244 (ARRY-142886), an inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2 kinase.
Chung EJ; Brown AP; Asano H; Mandler M; Burgan WE; Carter D; Camphausen K; Citrin D
Clin Cancer Res; 2009 May; 15(9):3050-7. PubMed ID: 19366835
[TBL] [Abstract][Full Text] [Related]
8. Riluzole enhances ionizing radiation-induced cytotoxicity in human melanoma cells that ectopically express metabotropic glutamate receptor 1 in vitro and in vivo.
Khan AJ; Wall B; Ahlawat S; Green C; Schiff D; Mehnert JM; Goydos JS; Chen S; Haffty BG
Clin Cancer Res; 2011 Apr; 17(7):1807-14. PubMed ID: 21325066
[TBL] [Abstract][Full Text] [Related]
9. The mTORC1/mTORC2 inhibitor AZD2014 enhances the radiosensitivity of glioblastoma stem-like cells.
Kahn J; Hayman TJ; Jamal M; Rath BH; Kramp T; Camphausen K; Tofilon PJ
Neuro Oncol; 2014 Jan; 16(1):29-37. PubMed ID: 24311635
[TBL] [Abstract][Full Text] [Related]
10. Cooperation of the HDAC inhibitor vorinostat and radiation in metastatic neuroblastoma: efficacy and underlying mechanisms.
Mueller S; Yang X; Sottero TL; Gragg A; Prasad G; Polley MY; Weiss WA; Matthay KK; Davidoff AM; DuBois SG; Haas-Kogan DA
Cancer Lett; 2011 Jul; 306(2):223-9. PubMed ID: 21497989
[TBL] [Abstract][Full Text] [Related]
11. Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair.
Lee JH; Choy ML; Ngo L; Foster SS; Marks PA
Proc Natl Acad Sci U S A; 2010 Aug; 107(33):14639-44. PubMed ID: 20679231
[TBL] [Abstract][Full Text] [Related]
12. Histone deacetylase inhibitor vorinostat suppresses the growth of uterine sarcomas in vitro and in vivo.
Hrzenjak A; Moinfar F; Kremser ML; Strohmeier B; Petru E; Zatloukal K; Denk H
Mol Cancer; 2010 Mar; 9():49. PubMed ID: 20202195
[TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo radiosensitization induced by the DNA methylating agent temozolomide.
Kil WJ; Cerna D; Burgan WE; Beam K; Carter D; Steeg PS; Tofilon PJ; Camphausen K
Clin Cancer Res; 2008 Feb; 14(3):931-8. PubMed ID: 18245557
[TBL] [Abstract][Full Text] [Related]
14. MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo.
Fournel M; Bonfils C; Hou Y; Yan PT; Trachy-Bourget MC; Kalita A; Liu J; Lu AH; Zhou NZ; Robert MF; Gillespie J; Wang JJ; Ste-Croix H; Rahil J; Lefebvre S; Moradei O; Delorme D; Macleod AR; Besterman JM; Li Z
Mol Cancer Ther; 2008 Apr; 7(4):759-68. PubMed ID: 18413790
[TBL] [Abstract][Full Text] [Related]
15. Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat.
Tate CR; Rhodes LV; Segar HC; Driver JL; Pounder FN; Burow ME; Collins-Burow BM
Breast Cancer Res; 2012 May; 14(3):R79. PubMed ID: 22613095
[TBL] [Abstract][Full Text] [Related]
16. A novel small molecule hybrid of vorinostat and DACA displays anticancer activity against human hormone-refractory metastatic prostate cancer through dual inhibition of histone deacetylase and topoisomerase I.
Yu CC; Pan SL; Chao SW; Liu SP; Hsu JL; Yang YC; Li TK; Huang WJ; Guh JH
Biochem Pharmacol; 2014 Aug; 90(3):320-30. PubMed ID: 24915421
[TBL] [Abstract][Full Text] [Related]
17. The histone deacetylase inhibitor vorinostat selectively sensitizes fibrosarcoma cells to chemotherapy.
Sampson ER; Amin V; Schwarz EM; O'Keefe RJ; Rosier RN
J Orthop Res; 2011 Apr; 29(4):623-32. PubMed ID: 20957741
[TBL] [Abstract][Full Text] [Related]
18. Combined inhibition of EZH2 and histone deacetylases as a potential epigenetic therapy for non-small-cell lung cancer cells.
Takashina T; Kinoshita I; Kikuchi J; Shimizu Y; Sakakibara-Konishi J; Oizumi S; Nishimura M; Dosaka-Akita H
Cancer Sci; 2016 Jul; 107(7):955-62. PubMed ID: 27116120
[TBL] [Abstract][Full Text] [Related]
19. Enhancement of in vitro and in vivo tumor cell radiosensitivity by valproic acid.
Camphausen K; Cerna D; Scott T; Sproull M; Burgan WE; Cerra MA; Fine H; Tofilon PJ
Int J Cancer; 2005 Apr; 114(3):380-6. PubMed ID: 15578701
[TBL] [Abstract][Full Text] [Related]
20. Preclinical activity of the rational combination of selumetinib (AZD6244) in combination with vorinostat in KRAS-mutant colorectal cancer models.
Morelli MP; Tentler JJ; Kulikowski GN; Tan AC; Bradshaw-Pierce EL; Pitts TM; Brown AM; Nallapareddy S; Arcaroli JJ; Serkova NJ; Hidalgo M; Ciardiello F; Eckhardt SG
Clin Cancer Res; 2012 Feb; 18(4):1051-62. PubMed ID: 22173548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
